Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
What the film says
CAR T cells against CD19 are now standard for some relapsed leukemias and lymphomas. Most carry one of two co-stimulatory signals, and are made by companies at high doses.
The idea: give the cells both signals at once, make them in the hospital's own lab, and ask how few are enough.
At Heidelberg University Hospital, patients' T cells receive a third-generation receptor carrying CD28 and 4-1BB together, aiming for longer-lived cells. Doses were escalated across adults and children.
In thirteen adults with relapsed acute lymphoblastic leukemia, eight of ten evaluable reached complete remission with no neurotoxicity. In nine heavily pretreated CLL patients, six reached complete remission.
HD-CAR-1, led by Michael Schmitt, continues in Heidelberg, from age three. Public record; not medical advice.
Sources behind this film
Schubert ML. BMJ Open, 2019
Approved CD19 CAR T use second-generation designs with either CD28 or 4-1BB; Third-generation RV-SFG.CD19.CD28.4-1BBzeta; in-house manufacturing
Schubert ML. J Hematol Oncol, 2023
Third-generation RV-SFG.CD19.CD28.4-1BBzeta; in-house manufacturing; 13 adults with r/r ALL; 8/10 evaluable CR; no ICANS; no ≥ grade 3 CRS
Third-generation RV-SFG.CD19.CD28.4-1BBzeta; in-house manufacturing; Michael Schmitt; Heidelberg; ages ≥3 (pediatric stratum III)
Yousefian S. Nat Commun, 2026
Low-dose question
Derigs P. Leukemia, 2024
9 CLL patients; 6 (67%) CR by day 90
The drug
Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose Level 3: 20×10^6 transduced cells/m^2; Dose Level 4: 5x10^7 transduced cells/m^2; Dose Level 5: 10x10^7 transduced cells/m^2; Dose Level 6: 20x10^7 transduced cells/m^2
3 days of cyclophosphamide 500 mg/m^2/day
The study
Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle cell lymphoma (MCL) (stratum II) as well as paediatric patients with r/r ALL (stratum III) will be treated with autologous T-lymphocytes transduced by the third-generation RV-SFG.CD19.CD28.4-1BBzeta retroviral vector.
The main purpose of this study is to evaluate safety and feasibility of escalating CD19.CAR T cell doses (0,1-20×20^7 transduced cells/m^2) after lymphodepletion with fludarabine and cyclophosphamide.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.